Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1982 2
1983 3
1984 2
1985 4
1986 5
1987 4
1988 3
1989 4
1990 7
1991 4
1992 1
1993 2
1994 3
1995 5
1996 5
1997 10
1998 11
1999 11
2000 19
2001 12
2002 6
2003 12
2004 15
2005 17
2006 13
2007 18
2008 20
2009 20
2010 19
2011 29
2012 40
2013 31
2014 32
2015 31
2016 37
2017 34
2018 30
2019 31
2020 26
2021 27
2022 25
2023 20
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

579 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Primary Peritoneal Undifferentiated Carcinoma"
Page 1
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Coleman RL, et al. Lancet Oncol. 2017 Jun;18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. Epub 2017 Apr 21. Lancet Oncol. 2017. PMID: 28438473 Free PMC article. Clinical Trial.
METHODS: The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged 18 years) with recurrent measurable or …
METHODS: The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres …
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S, Cosentino F, Scambia G. Fagotti A, et al. Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664. doi: 10.1136/ijgc-2020-001640. Epub 2020 Oct 7. Int J Gynecol Cancer. 2020. PMID: 33028623 Clinical Trial.
OBJECTIVE: To investigate whether neoadjuvant chemotherapy followed by interval debulking surgery is superior to primary debulking surgery in terms of perioperative complications and progression-free survival, in advanced epithelial ovarian, fallopian tube or primary …
OBJECTIVE: To investigate whether neoadjuvant chemotherapy followed by interval debulking surgery is superior to primary debulking su …
Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.
Kan T, Zhang S, Zhou S, Zhang Y, Zhao Y, Gao Y, Zhang T, Gao F, Wang X, Zhao L, Yang M. Kan T, et al. Oncogene. 2022 Feb;41(6):895-906. doi: 10.1038/s41388-021-02139-z. Epub 2022 Jan 7. Oncogene. 2022. PMID: 34992217
Epithelial ovarian cancers (EOCs) are sensitive to chemotherapy but will ultimately relapse and develop drug resistance. The origin of EOC recurrence has been elusive due to intra-tumor heterogeneity. Here we performed single-cell RNA sequencing (scRNA-seq) in 13,369 cells …
Epithelial ovarian cancers (EOCs) are sensitive to chemotherapy but will ultimately relapse and develop drug resistance. The origin of EOC …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Coleman RL, et al. Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Lancet. 2017. PMID: 28916367 Free PMC article. Clinical Trial.
BACKGROUND: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. ...Eligible patients were aged 18 years or older, had a platin …
BACKGROUND: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbour …
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Gershenson DM, et al. J Clin Oncol. 2017 Apr 1;35(10):1103-1111. doi: 10.1200/JCO.2016.71.0632. Epub 2017 Feb 21. J Clin Oncol. 2017. PMID: 28221866 Free PMC article.
Purpose The purpose of this study was to examine outcomes associated with hormonal maintenance therapy (HMT) compared with routine observation (OBS) after primary cytoreductive surgery and platinum-based chemotherapy in women with stage II to IV low-grade serous carcino …
Purpose The purpose of this study was to examine outcomes associated with hormonal maintenance therapy (HMT) compared with routine observati …
Pseudomyxoma peritonei.
Hinson FL, Ambrose NS. Hinson FL, et al. Br J Surg. 1998 Oct;85(10):1332-9. doi: 10.1046/j.1365-2168.1998.00882.x. Br J Surg. 1998. PMID: 9782010 Review.
RESULTS AND CONCLUSIONS: There is increasing evidence that pseudomyxoma peritonei is a neoplastic condition which usually arises from a primary adenoma or adenocarcinoma of the appendix. Reported series include a spectrum of pathological lesions, from entirely benign ruptu …
RESULTS AND CONCLUSIONS: There is increasing evidence that pseudomyxoma peritonei is a neoplastic condition which usually arises from a p …
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C, Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T. Sait Bakir M, et al. J BUON. 2021 Jul-Aug;26(4):1271-1278. J BUON. 2021. PMID: 34564981 Free article.
PURPOSE: The cost-effectiveness of bevacizumab has been the subject of debate, and we aimed to present our own retrospective data on its effect on survival in recurrent epithelial ovarian cancer. METHODS: Patients with recurrent ovarian, tubal and primary …
PURPOSE: The cost-effectiveness of bevacizumab has been the subject of debate, and we aimed to present our own retrospective data on its eff …
Cytoreductive surgery for advanced ovarian cancer.
Pölcher M, Zivanovic O, Chi DS. Pölcher M, et al. Womens Health (Lond). 2014 Mar;10(2):179-90. doi: 10.2217/whe.14.4. Womens Health (Lond). 2014. PMID: 24601809 Free article. Review.
Thus, the surgical management of advanced ovarian, primary peritoneal and fallopian tube cancers now incorporates more comprehensive surgical procedures. ...This review acknowledges controversies and aims to discuss novel developments in the field of cytoreductive s …
Thus, the surgical management of advanced ovarian, primary peritoneal and fallopian tube cancers now incorporates more compreh …
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Swisher EM, et al. Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29. Lancet Oncol. 2017. PMID: 27908594 Free article. Clinical Trial.
In ARIEL2 Part 1, patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma were classified into one of three predefined homologous recombination deficiency subgroups on the basis of tumour mutational analysis: BRCA mutant (deleterious germline or so …
In ARIEL2 Part 1, patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma were classified into one of three …
Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas.
Arias-Diaz AE, Ferreiro-Pantin M, Barbazan J, Perez-Beliz E, Ruiz-Bañobre J, Casas-Arozamena C, Muinelo-Romay L, Lopez-Lopez R, Vilar A, Curiel T, Abal M. Arias-Diaz AE, et al. Int J Mol Sci. 2023 Aug 25;24(17):13208. doi: 10.3390/ijms241713208. Int J Mol Sci. 2023. PMID: 37686015 Free PMC article.
Gynaecological serous carcinomas (GSCs) constitute a distinctive entity among female tumours characterised by a very poor prognosis. In addition to late-stage diagnosis and a high rate of recurrent disease associated with massive peritoneal carcinomatosis, th …
Gynaecological serous carcinomas (GSCs) constitute a distinctive entity among female tumours characterised by a very poor prognosis. …
579 results